Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice.

Lenfant F, Pizzato N, Liang S, Davrinche C, Le Bouteiller P, Horuzsko A.

J Gen Virol. 2003 Feb;84(Pt 2):307-17.

PMID:
12560562
2.

Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.

Rohrlich PS, Cardinaud S, Lulè J, Montero-Julian FA, Prodhomme V, Firat H, Davignon JL, Perret E, Monseaux S, Necker A, Michelson S, Lemonnier FA, Charneau P, Davrinche C.

Hum Immunol. 2004 May;65(5):514-22.

PMID:
15172452
3.
6.

Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells.

Arrode G, Boccaccio C, Lulé J, Allart S, Moinard N, Abastado JP, Alam A, Davrinche C.

J Virol. 2000 Nov;74(21):10018-24.

7.

Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion.

Besold K, Frankenberg N, Pepperl-Klindworth S, Kuball J, Theobald M, Hahn G, Plachter B.

J Gen Virol. 2007 May;88(Pt 5):1429-39.

PMID:
17412970
9.

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ.

Blood. 2002 Nov 15;100(10):3681-9. Epub 2002 Jul 12.

10.

Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.

Solache A, Morgan CL, Dodi AI, Morte C, Scott I, Baboonian C, Zal B, Goldman J, Grundy JE, Madrigal JA.

J Immunol. 1999 Nov 15;163(10):5512-8.

11.

Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus.

Akiyama Y, Maruyama K, Mochizuki T, Sasaki K, Takaue Y, Yamaguchi K.

Immunol Lett. 2002 Aug 1;83(1):21-30.

PMID:
12057851
12.

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.

Berencsi K, Gyulai Z, Gönczöl E, Pincus S, Cox WI, Michelson S, Kari L, Meric C, Cadoz M, Zahradnik J, Starr S, Plotkin S.

J Infect Dis. 2001 Apr 15;183(8):1171-9. Epub 2001 Mar 13.

PMID:
11262198
13.

Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.

Keever-Taylor CA, Margolis D, Konings S, Sandford GR, Nicolette CA, Lawendowski C, Burns WH.

Biol Blood Marrow Transplant. 2001;7(5):247-56.

14.

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.

McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR.

J Med Virol. 1994 May;43(1):103-10.

PMID:
8083644
16.
17.

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ.

Hum Immunol. 2000 Aug;61(8):764-79.

PMID:
10980387
19.

Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation.

Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M, Rauser G, Sinzger C, Jahn G, Loeffler J, Kanz L, Rammensee HG, Einsele H.

Blood. 2002 May 15;99(10):3830-7.

20.

HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.

Chen FE, Aubert G, Travers P, Dodi IA, Madrigal JA.

Cytotherapy. 2002;4(1):41-8.

PMID:
11953040

Supplemental Content

Support Center